valproic acid has been researched along with Muscular Dystrophy, Duchenne in 2 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Valproic acid (VPA) was found to enhance alpha7 integrin levels, induce muscle hypertrophy, and inhibit apoptosis in myotubes by activating the Akt/mTOR/p70S6K pathway." | 3.75 | Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. ( Burkin, DJ; Gurpur, PB; Kaufman, SJ; Liu, J, 2009) |
| "Skeletal muscles in animal models of Duchenne muscular dystrophy (DMD) are more susceptible to contraction-induced functional loss, which is not related to fatigue." | 1.91 | Valproic acid reduces muscle susceptibility to contraction-induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy. ( Agbulut, O; Delacroix, C; Ferry, A; Furling, D; Lemaitre, M; Moutachi, D, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moutachi, D | 1 |
| Lemaitre, M | 1 |
| Delacroix, C | 1 |
| Agbulut, O | 1 |
| Furling, D | 1 |
| Ferry, A | 1 |
| Gurpur, PB | 1 |
| Liu, J | 1 |
| Burkin, DJ | 1 |
| Kaufman, SJ | 1 |
2 other studies available for valproic acid and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Valproic acid reduces muscle susceptibility to contraction-induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy.
Topics: Animals; Desmin; Disease Models, Animal; Female; Mice; Mice, Inbred mdx; Muscle Contraction; Muscle, | 2023 |
Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy.
Topics: Animals; beta-Galactosidase; Carrier Proteins; Cell Culture Techniques; Disease Models, Animal; Enzy | 2009 |